美國Fluidigm  www.fluidigm.com www.fluidigm-china.com 
美國Fluidigm成立于1999年, Fluidigm公司開發(fā)、生產(chǎn)、銷售其獨(dú)有的集成流體通路（IFC）系統(tǒng)，能夠顯著提高生命科學(xué)研究的生產(chǎn)率。借助Fluidigm的集成流體通路，能夠?qū)O微量的試驗(yàn)對(duì)象同時(shí)進(jìn)行成千上萬次復(fù)雜的生化測(cè)定。這種生物學(xué)集成通路是通過在單一的微型設(shè)備上對(duì)液體處理部件進(jìn)行微型化和集成處理而實(shí)現(xiàn)的。Fluidigm公司的IFC系統(tǒng)由儀器、軟件和一次性使用的集成流體通路裝置組成，與傳統(tǒng)的實(shí)驗(yàn)室系統(tǒng)相比，該系統(tǒng)擴(kuò)大了通量，降低了成本，提高了靈敏度。Fluidigm公司的產(chǎn)品已獲得美國食品藥品管理局（FDA）的批準(zhǔn)，可用于診斷、檢定，且僅限于研究用途。 
Fluidigm公司的新款BioMark 96.96動(dòng)態(tài)陣列使用納升數(shù)量級(jí)的金標(biāo)準(zhǔn)TaqMan探針，能夠同時(shí)進(jìn)行9216個(gè)實(shí)時(shí)的PCR實(shí)驗(yàn)。這套新一代集成流體通路裝置能夠幫助生命科學(xué)研究人員進(jìn)一步達(dá)到新的成本水平，使后勤更加靈活和高效，并從微量的試樣中取得更完整的圖譜。
使用10uL的反應(yīng)量，將Fluidigm公司的新款96.96動(dòng)態(tài)陣列與業(yè)界標(biāo)準(zhǔn)的384微孔板系統(tǒng)比較，可以發(fā)現(xiàn)，96.96動(dòng)態(tài)陣列能夠顯著提高生產(chǎn)率和效率。 
——通量提高24倍：一個(gè)96.96動(dòng)態(tài)陣列能夠提供9216個(gè)并行的數(shù)據(jù)點(diǎn)，相當(dāng)于24塊384微孔板片的處理能力。
——master mix混合液的用量減少192倍：9216次反應(yīng)所需的混合液分別為：240微升和46080微升。 
——準(zhǔn)備過程的復(fù)雜度降低96倍：每進(jìn)行9216次反應(yīng)，96.96動(dòng)態(tài)陣列只需要192步移液操作，而為了準(zhǔn)備相同數(shù)量的微孔板片試驗(yàn)，需要完成18432步移液操作。
利用人類基因組序列以及有關(guān)癌癥表達(dá)基因的大量數(shù)據(jù)，Ludwig癌癥研究院正在進(jìn)行多項(xiàng)研究，試圖對(duì)癌癥中差異表達(dá)的基因進(jìn)行特征分析。Ludwig研究院Sandro J. de Souza博士說，“為了分析整個(gè)人類‘表面基因組’（surfaceome）的特征，我們進(jìn)行了一次大規(guī)模的分析。我們將基因表達(dá)數(shù)據(jù)整合到‘表面基因組’知識(shí)庫中，發(fā)現(xiàn)了可能在惡性膠質(zhì)瘤（glioblastoma）和結(jié)腸瘤中差異表達(dá)的待確定基因，接下來，我們想要用大規(guī)模的qPCR方法來驗(yàn)證部分待確定基因。在我們的qPCR研究階段，F(xiàn)luidigm公司的96.96動(dòng)態(tài)陣列將發(fā)揮至關(guān)重要的作用。”

富魯達(dá)(上海)儀器科技有限公司 
jane.liu@fluidigm.com
郵編:200051 
總機(jī):021 3255 8368 趙先生 13901972360 彭先生 13918037309 

Fluidigm develops and distributes systems based on integrated fluidic circuits (IFCs). Our systems can play a vital role in the advancement of today’s life science and allied fields, including molecular diagnostics, personalized medicine, and wildlife conservation. With IFCs, scientists are able, at last, to conceive of and implement large, complex studies that further our knowledge of biology.
The evolution of the life science may be compared to that of the electronics industry, in which the integrated circuit replaced transistors and wiring for routing electricity, sparking exponential increases in speed and complexity of computing. Like electronic circuits, IFCs are fabricated using a photo lithographic process, in this case, to pattern molds for producing silicone wafers that have microscopic channels, pumps, valves, and other components needed for the manipulation of nano-volume scale fluids. These components can be densely arrayed for parallel operations, without loss of reliability.
 
Every day, we strive to enhance our customers’ success through product innovation that continually drives down their cost per experiment. Our systems, including IFCs, instrumentation, and software, allow scientists to make incomparable leaps in productivity. Our product lines include:
The BioMark™ System for Genetic Analysis, 
The Fluidigm EP1 System for Genetic Analysis, and 
The TOPAZ® system for Protein Crystallization. 
The Company's patent portfolio consists of over 80 issued US patents and over 240 pending patents internationally, including those licensed from Caltech, Harvard, and University of Alabama.
Company Highlights
1999 Founding of Fluidigm Corporation (originally Mycometrix) to commercialize IFC technology developed in the laboratory of biophysicist Stephen Quake, PhD.

--------------------------------------------------------------------------------
2003 Launch of the TOPAZ® System for Protein Crystallization, including IFCs that assemble 768 crystallization conditions in parallel and instrumentation and software that automate the digital imaging and analysis of experiments.

--------------------------------------------------------------------------------
2004 Development of IP around a new class of IFCs referred to as dynamic arrays and of prototypes yielding as many as 9,216 parallel data points.

--------------------------------------------------------------------------------
2005 Opening of a 15,000 square-foot IFC fabrication facility in Singapore.

--------------------------------------------------------------------------------
2006 Launch of the BioMark™ Real-Time PCR System, a multi-application hardware/software platform based on BioMark™ dynamic arrays. Introduction of BioMark™ digital arrays, heralded as a practical solution for ultra-sensitive detection by digital PCR.

--------------------------------------------------------------------------------
2007 Launch of high-throughput genotyping on the BioMark system, a breakthrough for the study of genetic variation within large populations.

--------------------------------------------------------------------------------
2008 Launch of the Fluidigm® EP1 System for genetic analysis.